Michael Joseph Campa, Ph.D.

Associate Professor in Radiology

Department:
Radiology

Division:
Radiology - General

Email:
campa002mcdukeedu

Mailing Address:
Box 2610, DUMC
Durham, NC 27710

Telephone:
919-684-5285

Training:
Ph.D., University of Florida School of Medicine

Last Updated:
August 25, 2009

Research Interests:
There is longstanding evidence that invasive lung cancer is the end result of a multi-step process in which progressive molecular changes herald and accompany cytomorphologic changes. Our knowledge of these molecular events and the specific markers associated with the evolution from initiation to invasion is only partial. A number of specific biomarkers involved in oncogene activation or inactivation of tumor suppressor genes have been identified, but no single marker to date has been shown to have sufficient sensitivity, specificity, and predictive value to stratify all individuals. More likely, panels of markers will require development to best characterize the molecular profiles of susceptible individuals.

Our laboratory is engaged in studies designed to identify novel biomarkers of cancer. We have identified several serum proteins that, when taken together, may signify the presence of cancer. In addition, some of these biomarkers are associated with disease outcome. Hence, the have the potential to predict the course of the disease and help determine the most effective therapeutic strategy.

A different, but related, area of interest of our laboratory is the development of novel antibody-based ligands against cancer-specific molecules for use as non-invasive diagnostic imaging agents. The primary method that we use for identifying these novel ligands is by screening phage-displayed antibody libraries. We constructed the libraries using mRNA isolated from peripheral blood lymphocytes from a llama that had been immunized with various proteins and cell lines. We chose the llama as a source of antibody because they possess a particular type of IgG consisting of only heavy chain. By cloning only the antigen-binding portion of these heavy chain-only antibodies into the library, we were able to decrease the size of the resulting binding moiety by a factor of 10 compared to full-length heavy- and light-chain antibodies. Due to their small size, these so-called nanobodiesshould be able to penetrate tumors much more quickly than conventional IgG-based antibodies.

Publications:
2009 -- Gottlin, E. B., Xiangrong, Guan, Pegram, C., Cannedy, A., Campa, M. J., and Patz, E. F., Jr. (2009) Isolation of novel EGFR-specific VHH domains. J. Biomol. Screen. 14: 77-85.

2008 -- Hopper, E.D., Roulhac, P.L., Campa, M.J., Patz, E.F. Jr., Fitzgerald, M.C. Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. J. Amer. Soc. Mass Spec. 19(9): 1303-11, 2008.

2007 -- 8. Hoagland, 4th, L.F.M., Campa, M.J., Gottlin, E.B., Herndon, II, J.E., and Patz, Jr., E.F. (2007) Haptoglobin and Post-Translational Glycan Modified Derivatives as Serum Biomarkers for the Diagnosis of Non-Small Cell Lung Cancer. Cancer 110(10): 2260-2268.

2007 -- 9. Patz, Jr., E.F., Campa, M.J., Gottlin, E.B., Kusmartseva, I., Guan, X.R., and Herndon, II, J.E. (2007) Panel of Serum Biomarkers for the Diagnosis of Lung Cancer. J. Clin. Oncol. 25(35): 5578–5583.

2006 -- 7. Petersen, R.P., Campa, M.J., Sperlazza, J., Conlon, D., Joshi, M.-B., Harpole, D.H., and Patz, Jr., E.F. (2006) Tumor infiltrating Foxp3(+) regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107(12): 2866-72.

2005 -- 6. Howard, B.A., Furumai, R., Campa, M.J., Rabbani, Z.N., Vujaskovic, Z., Wang, X.F., and Patz, Jr., E.F. (2005) Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 65: 8853-8860.

2004 -- Suber, Jr., R.L., Flanders, V.L., Campa, M.J., and Patz, Jr., E.F. (2004) Accentuation of differentially expressed proteins using phage technology (ADEPPT). Anal. Biochem. 333: 351-357.

2004 -- Wang, M.Z., Shetty, J.T., Howard, B.A., Campa, M.J., Patz, Jr., E.F., and Fitzgerald, M.C. (2004) Thermodynamic analysis of cyclosporin A binding to cyclophilin A in a lung tumor tissue lysate. Anal. Chem. 76: 4343-4348.

2003 -- Pubmed # 12670919 -- Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003 Apr 1;63(7):1652-6.

2002 -- Pubmed # 12186442 -- Campa MJ, Serlin SB, Patz EF Jr. Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. Acad Radiol. 2002 Aug;9(8):927-32.

2000 -- Pubmed # 10964715 -- Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF Jr. Design of a novel small peptide targeted against a tumor-specific receptor. Biochem Biophys Res Commun. 2000 Aug 28;275(2):631-6.

1998 -- Pubmed # 9673405 -- Schreiber G, Campa MJ, Prabhakar S, O'Briant K, Bepler G, Patz EF Jr. Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res. 1998 May-Jun;18(3A):1787-92.

1996 -- Pubmed # 8603422 -- Campa MJ, Schreiber G, Bepler G, Bishop MJ, McNutt RW, Chang KJ, Patz EF Jr. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996 Apr 1;56(7):1695-701.

1996 -- Pubmed # 8884225 -- Campa MJ, McNutt RW, Hill JA, Patz EF, Chang KJ. Binding of [3H](+)-BW373U86 to delta-opioid receptors in rat brain membranes. Eur J Pharmacol. 1996 Aug 29;310(2-3):263-7.

1990 -- Pubmed # 2380194 -- Tarnuzzer RW, Campa MJ, Qian NX, Englesberg E, Kilberg MS. Expression of the mammalian system A neutral amino acid transporter in Xenopus oocytes. J Biol Chem. 1990 Aug 15;265(23):13914-7.

1989 -- Pubmed # 2592432 -- Campa MJ, Kilberg MS. Characterization of neutral and cationic amino acid transport in Xenopus oocytes. J Cell Physiol. 1989 Dec;141(3):645-52.